Our top pick for
Conformis, Inc is a medical devices business based in the US. Conformis shares (CFMS) are listed on the NASDAQ and all prices are listed in US Dollars. Conformis employs 262 staff and has a trailing 12-month revenue of around USD$72 million.
|52-week range||USD$0.5003 - USD$1.49|
|50-day moving average||USD$1.1126|
|200-day moving average||USD$0.8119|
|Wall St. target price||USD$2.33|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.515|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Conformis stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Conformis's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Conformis's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.21. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Conformis's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
|Revenue TTM||USD$72 million|
|Gross profit TTM||USD$36.7 million|
|Return on assets TTM||-18.73%|
|Return on equity TTM||-119.39%|
|Market capitalisation||USD$190.6 million|
TTM: trailing 12 months
There are currently 893,486 Conformis shares held short by investors – that's known as Conformis's "short interest". This figure is 35% up from 662,057 last month.
There are a few different ways that this level of interest in shorting Conformis shares can be evaluated.
Conformis's "short interest ratio" (SIR) is the quantity of Conformis shares currently shorted divided by the average quantity of Conformis shares traded daily (recently around 4.3 million). Conformis's SIR currently stands at 0.21. In other words for every 100,000 Conformis shares traded daily on the market, roughly 210 shares are currently held short.
However Conformis's short interest can also be evaluated against the total number of Conformis shares, or, against the total number of tradable Conformis shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Conformis's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Conformis shares in existence, roughly 10 shares are currently held short) or 0.0106% of the tradable shares (for every 100,000 tradable Conformis shares, roughly 11 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Conformis.
Find out more about how you can short Conformis stock.
We're not expecting Conformis to pay a dividend over the next 12 months.
Over the last 12 months, Conformis's shares have ranged in value from as little as $0.5003 up to $1.49. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Conformis's is 1.3367. This would suggest that Conformis's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Conformis, Inc., a medical technology company, develops, manufactures, and sells joint replacement implants. The company offers personalized knee replacement products, including iTotal CR, a cruciate-retaining product; iTotal PS, a posterior cruciate ligament substituting product; iDuo, a personalized bicompartmental knee replacement system; and iUni, a personalized unicompartmental knee replacement product to treat the medial or lateral compartment of the knee. It also provides Conformis Hip System, a hip replacement product; and iJigs, a customized single-use patient-specific instrumentation. The company markets and sells its products to hospitals and other medical facilities through sales force, independent sales representatives, and distributors in the United States, Germany, the United Kingdom, Austria, Ireland, Switzerland, Singapore, Hong Kong, Malaysia, Monaco, Hungary, Spain, and Australia. Conformis, Inc. was founded in 2004 and is headquartered in Billerica, Massachusetts.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.